Home > Insider Trading > Filing (0001209191-19-049104)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1080709	Arena Pharmaceuticals Inc	ARNA	Pharmaceutical Preparations (2834)	232908305

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1170362	W Steven Spector	C/O Arena Pharmaceuticals, Inc. 6154 Nancy Ridge Drive San Diego CA 92121	Evp, General Counsel & Sec	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-09-09	3,274	$32.50	22,964	No	4	M	Direct
Common Stock	Acquisiton	2019-09-09	5,810	$17.90	28,774	No	4	M	Direct
Common Stock	Acquisiton	2019-09-09	12,373	$15.50	41,147	No	4	M	Direct
Common Stock	Disposition	2019-09-09	21,200	$50.48	19,947	No	4	S	Direct
Common Stock	Disposition	2019-09-09	10,257	$51.23	9,690	No	4	S	Direct
Common Stock	Acquisiton	2019-09-10	12,627	$15.50	22,317	No	4	M	Direct
Common Stock	Disposition	2019-09-10	12,627	$50.28	9,690	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-09	3,274	$0.00	3,274	$32.50
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-09	5,810	$0.00	5,810	$17.90
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-09	12,373	$0.00	12,373	$15.50
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-10	12,627	$0.00	12,627	$15.50

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,726	2020-03-17	No	4	M	Direct
9,189	2022-12-15	No	4	M	Direct
40,127	2023-03-02	No	4	M	Direct
27,500	2023-03-02	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2, 3, and 4 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.59, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59, inclusive.
The options vested in four equal annual installments beginning on March 17, 2011, and were immediately exercisable once vested.
The options vest in four equal annual installments beginning on December 15, 2016, and are immediately exercisable once vested.
The options vest in four equal annual installments beginning on March 2, 2017, and are immediately exercisable once vested.